JUBILANT PHARMA LIMITED
(Company Registration No. 200506887H)
(Incorporated in the Republic of Singapore)
Registered office: 160 Robinson Road, #17-01 SBF Center, Singapore 068914

December 28, 2017

Singapore Exchange Securities Trading Limited
11 North Buona Vista Drive #06-07
The Metropolis Tower 2
Singapore 138589

Dear Sirs,

We enclose a communication pertaining to USFDA approval.

This is for your kind information and records.

Thanking you,

Yours faithfully,
For Jubilant Pharma Limited

Sanjay Bhartia
Chief Financial Officer

Encl.: as above

Jubilant Pharma Ltd.
6 Temasek Boulevard, #20-06
Suntec City Tower Four, Singapore 038986
Tel.: +65 6235 4129
www.jubilantpharma.com

Jubilant receives sNDA approval for new indications from USFDA for DRAXIMAGE® DTPA

Noida (UP), India, Thursday, December 28, 2017

Jubilant Pharma Limited, a material wholly owned subsidiary of Jubilant Life Sciences Ltd, through one of its wholly owned subsidiaries, has received a Supplemental New Drug Application (sNDA) approval from USFDA for DRAXIMAGE® DTPA (Kit for the Preparation of Technetium Tc99m Pentetate Injection) powder for solution.

Specifically, DRAXIMAGE® DTPA is a kit for the preparation of Technetium Tc99m pentetate injection. Technetium Tc99m pentetate is a radioactive diagnostic agent indicated for:

a) Brain imaging in adults

b) Renal visualization, assessment of renal perfusion and estimation of glomerular filtration rate in adult and pediatric patients

c) Lung ventilation imaging and evaluation of pulmonary embolism, when paired with perfusion imaging in adult and pediatric patients when administered by nebulizer for inhalation.

The expanded labeling incorporates a new route of administration and new indication which enhances the broad utility of DRAXIMAGE® DTPA to include clinical applications to image and diagnose key functional aspects of the pulmonary system, and will allow physicians to perform lung ventilation studies for a much larger patient population suffering from compromised pulmonary function. The product is immediately available in the US market.

Commenting on the occasion, Mr Shyam S Bhartia, Chairman & Managing Director, and Mr Hari S Bhartia, Director, said: “We are very pleased with the latest approval from US FDA for DRAXIMAGE® DTPA. It reinforces our commitment to continued investment in innovation, research and development. Our goal is to bring value to products that enable physicians to deliver high quality diagnostics imaging studies”

About Jubilant Pharma Limited

Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and a wholly owned subsidiary of Jubilant Life Sciences Limited, is an integrated global Pharmaceutical company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile and Non Sterile products. JPL has 6 USFDA approved manufacturing facilities in India, US and Canada, a network of over 50 radio-pharmacies in the US and R&D centres in India and

Canada. The Company has a team of around 3,500 multicultural people across the globe and is committed to deliver value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceutical companies globally.

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.